InfuSystem (INFU) director granted 24,890 stock options at $8.37 strike

Rhea-AI Filing Summary

InfuSystem Holdings director Paul Andrew Gendron received a new stock option grant as part of his compensation. He was granted options to acquire 24,890 shares of common stock at an exercise price of $8.37 per share, expiring in 2036. These options vest on May 12, 2027. Following the reported transactions, he directly holds 70,000 shares of InfuSystem common stock, indicating this filing reflects equity-based incentives rather than open-market buying or selling.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider GENDRON PAUL ANDREW

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	24,890	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 24,890 shares (Direct, null); Common Stock — 70,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 24,890 shares Exercise price: $8.37 per share Option vesting date: May 12, 2027 +2 more

5 metrics

Option grant size 24,890 shares Stock options granted to director on May 12, 2026

Exercise price $8.37 per share Strike price of stock options

Option vesting date May 12, 2027 Date options become exercisable

Option expiration date May 12, 2036 Last date options can be exercised

Shares held after filing 70,000 shares Common stock directly held following transactions

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vests

4 terms

Stock Option (right to buy) financial

"Security title is reported as Stock Option (right to buy) for this grant"

Grant, award, or other acquisition financial

"The transaction code description notes a Grant, award, or other acquisition"

exercise price financial

"The option has an exercise price of $8.37 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests financial

"The option vests on May 12, 2027 according to the footnote"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GENDRON PAUL ANDREW

(Last) (First) (Middle)

C/O INFUSYSTEM HOLDINGS, INC.

3851 WEST HAMLIN ROAD

(Street)

ROCHESTER HILLS MICHIGAN 48309

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
InfuSystem Holdings, Inc [ INFU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								70,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.37	05/12/2026		A		24,890		05/12/2027(1)	05/12/2036	Common Stock	24,890	$0	24,890	D

Explanation of Responses:

1. The option, representing the right to purchase 24,890 shares of InfuSystem Holdings, Inc. common stock, vests on May 12, 2027.

Remarks:

	/s/ Kevin Whitman, Attorney-in-Fact for Paul A. Gendron	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did InfuSystem (INFU) report for Paul Andrew Gendron?

InfuSystem reported that director Paul Andrew Gendron received a stock option grant for 24,890 shares of common stock. The options are part of his equity compensation and give him the right to buy shares at a fixed exercise price in the future.

What are the key terms of Paul Andrew Gendron’s new InfuSystem (INFU) stock options?

Gendron’s new stock options cover 24,890 shares of InfuSystem common stock at an exercise price of $8.37. The options vest on May 12, 2027 and expire on May 12, 2036, providing a long-dated incentive tied to future company performance.

Did Paul Andrew Gendron buy or sell InfuSystem (INFU) shares in this Form 4?

The Form 4 shows a grant of stock options to Paul Andrew Gendron, not an open-market purchase or sale. It records an equity award classified as an acquisition of derivative securities, which is typical compensation rather than a discretionary trading decision.

How many InfuSystem (INFU) shares does Paul Andrew Gendron hold after this filing?

After the reported transactions, Paul Andrew Gendron directly holds 70,000 shares of InfuSystem common stock. In addition, he has been granted 24,890 stock options that, once vested and exercised, could increase his effective economic exposure to the company’s equity.

When do Paul Andrew Gendron’s InfuSystem (INFU) stock options vest and expire?

The stock options granted to Paul Andrew Gendron vest on May 12, 2027, meaning they become exercisable on that date. They carry an expiration date of May 12, 2036, giving him a nine-year window after vesting to decide whether to exercise.